Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CHRS 
Coherus BioSciences Inc (CHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CHRS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.42% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 97.29M USD | Price to earnings Ratio 3.36 | 1Y Target Price 4.83 |
Price to earnings Ratio 3.36 | 1Y Target Price 4.83 | ||
Volume (30-day avg) 1901045 | Beta 0.93 | 52 Weeks Range 0.66 - 2.61 | Updated Date 04/1/2025 |
52 Weeks Range 0.66 - 2.61 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate -0.1305 | Actual -0.28 |
Profitability
Profit Margin 10.68% | Operating Margin (TTM) -65.65% |
Management Effectiveness
Return on Assets (TTM) -10.94% | Return on Equity (TTM) -1657.06% |
Valuation
Trailing PE 3.36 | Forward PE 41.15 | Enterprise Value 237353039 | Price to Sales(TTM) 0.36 |
Enterprise Value 237353039 | Price to Sales(TTM) 0.36 | ||
Enterprise Value to Revenue 0.89 | Enterprise Value to EBITDA 3.89 | Shares Outstanding 115897000 | Shares Floating 114413369 |
Shares Outstanding 115897000 | Shares Floating 114413369 | ||
Percent Insiders 1.35 | Percent Institutions 57.56 |
Analyst Ratings
Rating 4.43 | Target Price 5.9 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Coherus BioSciences Inc
Company Overview
History and Background
Coherus BioSciences, Inc. was founded in 2010 and is focused on developing and commercializing biosimilar therapeutics. They have evolved from primarily focusing on biosimilars to developing innovative immuno-oncology therapeutics.
Core Business Areas
- Biosimilars: Developing and commercializing biosimilars of established biologic drugs. These products aim to provide cost-effective alternatives to existing therapies.
- Immuno-oncology: Developing innovative immuno-oncology therapeutics, including novel antibodies and T-cell therapies, for cancer treatment.
Leadership and Structure
The leadership team includes Denny Lanfear (CEO), McDavid Stilwell (CFO) and other key executives. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Udenyca (pegfilgrastim-cbqv): Udenyca is a biosimilar to Neulasta (pegfilgrastim) used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Competitors include Amgen (Neulasta), Mylan (Fulphila). Market share fluctuates, but Udenyca has captured a significant portion of the pegfilgrastim biosimilar market. Market share is estimated to be 20-25% of the pegfilgrastim market.
- Cimberio (ranibizumab-eqrn): Cimberio is a biosimilar of Lucentis. Market share is still low and being launched by Coherus. Cimberio is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV). Competitors include Novartis (Lucentis), Regeneron (Eylea).
- Loqtorzi (toripalimab-tpzi): An anti-PD-1 monoclonal antibody for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). This is Coherus's novel immuno-oncology product. Competitors include Keytruda (Merck), Opdivo (Bristol Myers Squibb).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, stringent regulatory requirements, and high R&D costs. The biosimilars market is growing rapidly due to increasing cost pressures in healthcare. The immuno-oncology market is also rapidly growing with high unmet need.
Positioning
Coherus BioSciences is positioned as a player in both the biosimilars and immuno-oncology markets. Their competitive advantages include their expertise in biosimilar development and commercialization, and their expanding pipeline of innovative immuno-oncology therapies.
Total Addressable Market (TAM)
The global biosimilars market is projected to reach hundreds of billions of dollars. The immuno-oncology market is also in the hundreds of billions. Coherus is positioned to capture a growing share of both markets.
Upturn SWOT Analysis
Strengths
- Strong expertise in biosimilar development and commercialization
- Growing pipeline of innovative immuno-oncology therapies
- Established commercial infrastructure
- Strategic partnerships
Weaknesses
- Reliance on regulatory approvals
- Competition from larger pharmaceutical companies
- Relatively small size compared to major players
- Dependence on key products
Opportunities
- Expanding into new biosimilar markets
- Advancing immuno-oncology pipeline
- Acquiring or partnering with other companies
- Capitalizing on the increasing demand for affordable medicines
Threats
- Increased competition in the biosimilars market
- Changes in healthcare regulations
- Patent challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- AMGN
- VTRS
- SCLX
Competitive Landscape
Coherus competes with larger pharmaceutical companies in the biosimilars and immuno-oncology markets. They aim to differentiate themselves through innovation and cost-effectiveness.
Major Acquisitions
Surface Oncology
- Year: 2023
- Acquisition Price (USD millions): 65
- Strategic Rationale: Expand immuno-oncology pipeline with novel antibody therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by biosimilar sales. Immuno-oncology initiatives are aimed at generating future growth.
Future Projections: Future growth is dependent on successful development and commercialization of their pipeline products. Analyst projections vary.
Recent Initiatives: Recent initiatives include the launch of Cimberio and continued development of their immuno-oncology pipeline.
Summary
Coherus BioSciences is a mid-sized player in the biosimilar and immuno-oncology space. Their core strength lies in biosimilar development and commercialization; however, their future hinges on their newer immuno-oncology product pipeline. They face significant competition from larger pharmaceutical companies. The recent Surface Oncology acquisition should help their pipeline. CHRS needs to improve its overall debt issues and increase its equity.
Similar Companies
- AMGN
- VTRS
- BMY
- MRK
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, market research reports, financial news sources.
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coherus BioSciences Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-06 | Chairman, President & CEO Mr. Dennis M. Lanfear | ||
Sector Healthcare | Industry Biotechnology | Full time employees 228 | Website https://www.coherus.com |
Full time employees 228 | Website https://www.coherus.com | ||
Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. The company was incorporated in 2010 and is based in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.